Abstract:
Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
Abstract:
Disclosed is a method for promoting extracellular expression of proteins in B. subtilis using cutinase, which belongs to the technical fields of genetic engineering, enzyme engineering and microbial engineering. It teaches co-expressing a cutinase mutant and a target protein in B. subtilis to promote extracellular expression of the target protein which is naturally located inside cells. The target protein includes xylose isomerase, 4,6-α-glucosyltransferase, 4-α-glucosyltransferase, trehalose synthase, branching enzyme and the like. The invention can achieve extracellular expression of intracellularly localized target protein, improve the production efficiency, reduce the production cost and simplify the subsequent extraction process.
Abstract:
The present invention relates to the field of biotechnology engineering. It provides a recombinant Escherichia coli that can produce fructosylated chondroitin with high yields and the method for constructing the recombinant strain. The present invention discloses a method for constructing an expression plasmid pETM6R1-RBS-glmM-GGGS-glmS that contains a glmM and a glmS gene under regulation of ribosome binding sites. The recombinant plasmid was transformed into E. coli K4 to obtain a recombinant E. coli strain ZQ33 that can produce fructosylated chondroitin up to 3.99 g·L−1 by fed-batch fermentation in a 5-L fermentor, which was increased by 108.90% compared to that of the wild type strain.
Abstract:
An antenna module is provided in the present disclosure. The antenna module includes a printed circuit board and a metal frame surrounding the printed circuit board. The metal frame includes a metal radiating portion, and a first feed point, a second feed point, a first ground point and a second ground point are disposed on the printed circuit board and electrically connected to the metal radiating portion. The first feed point and the second feed point are symmetrically disposed at two opposite sides of a central axis of the printed circuit board; the first ground point and the second ground point are respectively disposed corresponding to the first feed point and the second feed point. The present disclosure also provides a mobile device using the antenna module.
Abstract:
A multi-band antenna includes a radiating antenna member, a first parasitic antenna member, and a second parasitic antenna member. The radiating antenna member includes a feeding unit, a high frequency (HF) radiating unit and a low frequency (LF) radiating unit, the HF radiating unit and the LF radiating unit extend from the feeding unit. The first parasitic antenna member includes an HF grounding part, and an HF parasitic unit extending from the HF grounding part and adjacent to the HF radiating unit. The second parasitic antenna member includes an LF grounding part, and an LF parasitic unit extending from the LF grounding part and electromagnetically coupled to the LF radiating unit. The feeding unit is arranged between the HF grounding part and the LF grounding part; the feeding unit and the HF radiating unit define a receiving slot, and the HF parasitic unit is arranged in the receiving slot.
Abstract:
The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.
Abstract:
A method and system for providing a magnetic junction residing on a substrate and usable in a magnetic device are described. The magnetic junction includes a first pinned layer, a first nonmagnetic spacer layer having a first thickness, a free layer, a second nonmagnetic spacer layer having a second thickness greater than the first thickness, and a second pinned layer. The first nonmagnetic spacer layer resides between the pinned layer and the free layer. The first pinned layer resides between the free layer and the substrate. The second nonmagnetic spacer layer is between the free layer and the second pinned layer. Further, the magnetic junction is configured such that the free layer is switchable between a plurality of stable magnetic states when a write current is passed through the magnetic junction.
Abstract:
The present invention provides a method of increasing extracellular secretion of secretory proteins by co-expressing the secretory proteins with a mature cutinase. Cutinase can improve the permeability of E. coli cell membrane without destroying the membrane, and thus facilitate cross-membrane transfer of the secretory proteins co-expressed in E. coli. Increased extracellular secretion of target proteins can shorten cell culture time, reduce the formation of inclusion bodies and increase production of target proteins.
Abstract:
A system that transfers energy wirelessly includes a transmitter of the energy and a receiver of the energy. A housing made of a material that approximates properties of a perfect magnetic conductor. The housing is arranged to direct a magnetic field from the transmitter to the receiver to improve an efficiency of the energy transfer from the transmitter to the receiver.
Abstract:
This invention is directed to acylated amino acid amidyl pyrazoles and related compounds of Formula I. The invention is also directed to a pharmaceutical formation comprising such compound or in a pharmaceutically acceptable salt form thereof. The invention is further directed to a method for inhibiting β-amyloid peptide release and/or synthesis, a method for inhibiting γ-secretase activity, and a method for treating neurological disorders associated with β-amyloid peptide production. The method comprises administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula I. The compounds of Formula I are useful in the prevention and treatment of Alzheimer's disease.